Italia markets closed
  • FTSE MIB

    19.285,41
    +208,46 (+1,09%)
     
  • Dow Jones

    28.335,57
    -28,09 (-0,10%)
     
  • Nasdaq

    11.548,28
    +42,28 (+0,37%)
     
  • Nikkei 225

    23.516,59
    +42,32 (+0,18%)
     
  • Petrolio

    39,78
    -0,86 (-2,12%)
     
  • BTC-EUR

    10.945,55
    +73,82 (+0,68%)
     
  • CMC Crypto 200

    260,05
    -1,40 (-0,54%)
     
  • Oro

    1.903,40
    -1,20 (-0,06%)
     
  • EUR/USD

    1,1868
    +0,0042 (+0,36%)
     
  • S&P 500

    3.465,39
    +11,90 (+0,34%)
     
  • HANG SENG

    24.918,78
    +132,65 (+0,54%)
     
  • Euro Stoxx 50

    3.198,86
    +27,45 (+0,87%)
     
  • EUR/GBP

    0,9096
    +0,0063 (+0,69%)
     
  • EUR/CHF

    1,0723
    +0,0000 (+0,00%)
     
  • EUR/CAD

    1,5567
    +0,0044 (+0,28%)
     

Athira Pharma prices upsized IPO at $17, high end of price range

Ciara Linnane
·1 minuto per la lettura

Athira Pharma Inc. priced its initial public offering at $17 a share, the top end of its proposed price range. The company upsized the deal to 12 million shares from an original plan to offer 10 million shares, to raise $204 million. The stock will start trading on Nasdaq later Friday, under the ticker "ATHA." Goldman Sachs, Jefferies and Stifel were lead book runners on the deal with JMP Securities acting as co-manager. Proceeds will be used to finance clinical trials. "We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration," the company says in its IPO prospectus.